The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.
Specifically, this RFP focuses on:
- developing novel PET ligands for clinical use
- supporting novel CSF biomarkers
- validating established MRI approaches in larger cohorts
Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include:
- Neuronal loss
- Vascular injury and blood-brain barrier integrity
- Mitochondria and metabolic function
- Protein misfolding/proteostasis
- Oxidative stress
- White matter changes
- Other novel targets supported by compelling biological rationale and connection to disease
The ADDF has limited interest in CSF measures of amyloid and tau.
